Selected Grants
Alexion ALXN1720-MG-301
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2023 - 2028Deciphering Immunological Biomarkers in Myasthenia Gravis by Using Multi-omics
ResearchSignificant Contributor · Awarded by Myasthenia Gravis Foundation · 2024 - 2026Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2020 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2024 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2019 - 2025Alexion ALXN1720-MG-301
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2023 - 2028Deciphering Immunological Biomarkers in Myasthenia Gravis by Using Multi-omics
ResearchSignificant Contributor · Awarded by Myasthenia Gravis Foundation · 2024 - 2026Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
ResearchPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2020 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2024 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2019 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Site Agreement)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2019 - 2025RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS
ResearchPrincipal Investigator · Awarded by The George Washington University · 2021 - 2024A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients with Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2019 - 2023RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (ADAPT)
ResearchPrincipal Investigator · Awarded by The George Washington University · 2020 - 2023PROMISE-MG: PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY OF COMPARATIVE EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MYASTHENIA GRAVIS
ResearchPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2017 - 2021A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2019AANEM Autoimmune Neuromuscular Disorders Fellowship
FellowshipAdvisor · Awarded by AANEM Foundation for Research & Education · 2017 - 2018A Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Generalized Refractory Myasthenia Gravis (GMG)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2014 - 2017External Relationships
- Accordant Health Services
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Amgen, Inc.
- Immunovant
- Janssen Scientific Affairs
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.